drug delivery systems

Novel nanomedicines for resolving inflammation as a treatment for type 2 diabetes

This project proposes a new nanomedicine approach to treat type 2 diabetes (T2D). Studies in humans and mice have shown that inflammation in fat tissues and the pancreas is a major driving force for the development of obesity-induced insulin resistance and diabetes. A major limitation of current drugs is that they distribute over the entire body, exposing all cell types, while only a small amount reaches the desired target cells at disease sites, such as macrophages in inflamed tissues. This results in limited drug efficacy and unwanted side-effects.

Primary Investigator: 
Year: 
2019

A GlycoCaged drug delivery system to improve the treatment of inflammatory bowel disease

Inflammatory bowel disease (IBD) is lifelong, debilitating condition that afflicts one in every 150 Canadians. Worryingly, the number of people diagnosed with IBD is rising worldwide, including among new Canadians and children. There is currently no cure for IBD, so treatment options are limited to managing symptoms with anti-inflammatory drugs.

Primary Investigator: 
Year: 
2019

Development of a novel intranasal oligonucleotide delivery approach for Huntington disease

Huntington disease (HD) is a progressive brain disorder affecting movement, mood, and cognitive skills, caused by inheriting a mutated copy of the huntingtin gene. This results in the production of a mutant huntingtin protein (mHTT) that is toxic to critical nerve cells in the brain. Reducing mHTT using specialized pieces of DNA, called antisense oligonucleotides (ASOs), should slow or prevent disease onset.

Primary Investigator: 
Award Type: 
Year: 
2019

Don’t sugar coat it: Cardiac consequences of developing Type 2 diabetes after spinal cord injury

Michael Smith Foundation for Health Research/Rick Hansen Institute (RHI)/International Collaboration on Repair Discoveries (ICORD) Post-Doctoral Fellowship Award

People with spinal cord injury (SCI) are at an increased risk of developing type 2 diabetes. Currently, no studies have investigated type 2 diabetes in people with SCI. We believe it may contribute to the high rate of heart disease among people with SCI.

Primary Investigator: 
Award Type: 
Year: 
2015
Subscribe to RSS - drug delivery systems